A Guide to Parkinson’s Disease Medications

Parkinson’s Disease Medications: A Complete Guide

Parkinson’s Disease Medications: A Complete Guide
iStock

Parkinson’s disease cannot be cured, but different types of medications can help treat its symptoms.

Parkinson’s is best known for causing symptoms related to movement (known as “motor symptoms”), such as tremors, muscle stiffness, slow movement (bradykinesia), and impaired balance. But it can also cause nonmotor, or nonmovement, symptoms, such as dementia; psychosis, or loss of contact with reality; mood disorders such as depression, anxiety, and apathy; and sleep disorders such as insomnia.

Many of the symptoms of Parkinson’s are the result of a loss of neurons in the brain that produce the neurotransmitter (or chemical messenger) dopamine.

Not surprisingly then, many of the treatments for Parkinson’s disease either raise the level of dopamine in the brain or attempt to mimic its effect.

Medications for Parkinson’s disease fall into three general categories:

  • Medications that increase the level of dopamine in your brain
  • Medications that affect other neurotransmitters, to help control motor symptoms
  • Medications that help control nonmotor symptoms
Treating Parkinson’s disease with medication can be a balancing act between managing the symptoms of the disease and managing drug side effects.

Dopamine-Focused Medications

The following prescription drugs help to regulate the amount of dopamine in the brain.

The American Academy of Neurology (AAN) has guidelines on different drug therapy options to help patients with early-stage Parkinson’s disease control motor symptoms.

Dopamine-Increasing Medication

Dopamine can’t be taken directly as a treatment because it’s broken down in the body before it reaches the brain. As a result, the most common and effective treatment of motor symptoms related to Parkinson’s disease is a combination of the drugs levodopa and carbidopa.

This drug combination, sometimes called L-DOPA, eventually becomes dopamine that your brain can use. The levodopa can temporarily help replace some of the lost dopamine in the brain, and the carbidopa helps improve the uptake of levodopa by preventing it from being activated into dopamine before it reaches the brain.

These drugs are sold under the brand names Duopa, Rytary, and Sinemet.

In 2024, the U.S. Food and Drug Administration (FDA) approved two new levodopa and carbidopa medications for people with Parkinson’s disease.

In August, the FDA approved a new long-acting oral formula of levodopa and carbidopa, called Crexont. It aims to relieve more symptoms with fewer medication doses.

In October, the agency approved an infusion-based version called Vyalev. This medication is the first and only version where levodopa is administered by a continuous pump similar to the insulin pumps used by people with diabetes.

Levodopa is considered superior to other common Parkinson’s disease medications such as dopamine agonists for managing motor symptoms early in the disease.

However, it’s also more likely to cause a type of uncontrolled, involuntary movement called dyskinesia that can include fidgeting, writhing, head bobbing, and body swaying.

To minimize the risk of dyskinesia, doctors often prescribe the lowest effective dose of levodopa and monitor patients for dyskinesia and other side effects over time.

Possible side effects of levodopa also include:

  • Nausea
  • Vomiting
  • Sleepiness
  • Orthostatic hypotension, or low blood pressure that occurs when sitting or standing up

In early Parkinson’s, taking levodopa with meals may decrease nausea.

However, in later stages of the disease, eating while taking the medication may decrease the drug’s effectiveness due to food competing with levodopa for absorption from the gut.

People who use levodopa sometimes experience “wearing off” or “off episodes,” in which motor symptoms occur between medication doses, or even mid-dose. Off episodes can come on gradually or suddenly.

Certain drug treatments have been developed specifically to treat these off episodes. These include Inbrija, an orally inhaled form of levodopa, and istradefylline (Nourianz), a medication taken alongside levodopa.

Stopping levodopa abruptly can cause unpleasant withdrawal symptoms, including:

  • Fever
  • Rigid muscles
  • Unusual body movements
  • Confusion

For this reason, you should never change your dose of levodopa or stop taking it suddenly without first talking to your doctor.

Dopamine-Mimicking Drugs

Dopamine agonists are medications that mimic the action of dopamine in the brain and can have side effects similar to those of levodopa.

This group of drugs includes the following:

  • apomorphine (Apokyn, Kynmobi)
  • pramipexole (Mirapex)
  • rotigotine (Neupro)
  • bromocriptine (Parlodel)
  • droxidopa (Northera)

  • ropinirole (Requip)
In rare cases, these medications may cause an uncontrollable desire to gamble, shop, or have sex, collectively known as impulse control disorders.

Dopamine agonists can cause multiple side effects, including impulse control disorders, excessive daytime sleepiness, and suddenly falling asleep (sleep attacks). They can also increase the risk of hallucinations and feeling lightheaded when standing up.

People who are in the early stages of Parkinson’s disease should talk with their doctor about the potential benefits and risks of these medications before starting any of them due to individual risk factors.

MAO-B Inhibitors

These medications inhibit the enzyme monoamine oxidase B (MAO-B), which breaks down dopamine in the brain. As a result, these medications help dopamine stay intact for your brain to use.

These medications include rasagiline (Azilect), safinamide (Xadago), and selegiline (Emsam).

Sometimes, a MAO-B inhibitor is taken with levodopa to prolong the effect of that drug.

Common side effects of MAO-B inhibitors include:

  • Mild nausea
  • Dry mouth
  • Lightheadedness
  • Constipation

Taking these drugs at the same time as certain antidepressants and sedatives should be avoided or monitored closely by your doctor because of potentially dangerous interactions.

MAO-B inhibitors are considered less effective than levodopa at improving mobility in early Parkinson’s and are additionally associated with a higher risk of drug discontinuation because of side effects.

COMT Inhibitors

These medications help stop another enzyme that breaks down dopamine in the brain, catechol-O-methyltransferase (COMT). This group of drugs includes entacapone (Comtan), opicapone (Ongentys), and tolcapone (Tasmar).

Taken with levodopa, they prolong that drug’s effect. They may be prescribed if a person is experiencing “wearing off” between doses of levodopa.

The most common side effect of COMT inhibitors is diarrhea. They may also cause sleep disturbances, dizziness, or hallucinations.

Tasmar has been shown to cause severe liver disease in some people, so you may need to undergo regular blood tests to assess your liver function if you take it.

Amantadine (Symmetrel)

Amantadine (Symmetrel) is an antiviral medication that may increase the effects of dopamine in the brain. Researchers are unsure why amantadine helps in this area.

Amantadine is sometimes taken by itself early in the course of Parkinson’s disease. It may also be taken later on to help with dyskinesia caused by levodopa.

Medications That Affect Other Neurotransmitters

Other medications target different neurotransmitters to mitigate symptoms of Parkinson’s.

Anticholinergics 

Anticholinergics can be helpful for reducing tremor and muscle contractions associated with “wearing off.” They work by reducing the action of a neurotransmitter called acetylcholine that is involved in activating muscles.

This group of drugs includes trihexyphenidyl (Artane), benztropine (Cogentin), scopolamine (Transderm-Scop), and ethopropazine (Parsidol).

Side effects of anticholinergics may include:

  • Blurred vision
  • Dry mouth, constipation
  • Urinary retention
In older people, especially, they can cause confusion and hallucinations, so they are not recommended for people older than age 70.

Medications Treating Nonmovement Symptoms

While many medications focus on motor symptoms that are a hallmark of Parkinson’s disease, a host of drugs are also used to help various nonmotor or nonmovement symptoms of Parkinson’s disease.

Antipsychotics

These drugs are used to treat the hallucinations and delusions that some people with Parkinson’s disease experience.

Quetiapine (Seroquel), clozapine (Clozaril), and pimavanserin (Nuplazid) appear to be safe and well tolerated among people with Parkinson’s. These antipsychotic medications don’t worsen Parkinson’s symptoms as much as other ones do.

Antidepressants 

Depression is common in people with Parkinson’s disease. If you’re feeling extreme sadness or lack interest in activities you once enjoyed, trying an antidepressant or nonmedication treatment like cognitive behavioral therapy may help.

Before prescribing an antidepressant, your doctor will want to know about any herbal supplements that you take, as well as any drug and alcohol use, since antidepressants may interact with these substances (and with some drugs for Parkinson’s disease).

Stimulants 

These drugs are often used to treat excessive daytime sleepiness in people with Parkinson’s disease.

If a sleep disorder persists in spite of efforts to address underlying causes (like pain or frequent urination), then your doctor may prescribe a medication like modafinil (Provigil) to reduce sleepiness during the day.

Cholinesterase Inhibitors 

These drugs are used to treat dementia, or memory and thinking problems, due to aging and the progression of Parkinson’s disease.

Medications like donepezil (Aricept), rivastigmine (Exelon), memantine (Namenda), and galantamine (Razadyne) were developed for Alzheimer’s disease, but they may also help with dementia in people with Parkinson’s.

Medications
What it Does
Levodopa and Carbidopa
This is the most common and effective treatment for motor symptoms. Levodopa can temporarily help replace some of the lost dopamine in the brain, and carbidopa helps improve the uptake of levodopa.
Dopamine agonists
These are medications that mimic the action of dopamine in the brain and can have side effects similar to those of levodopa.
MAO-B inhibitors
These medications inhibit the enzyme monoamine oxidase B (MAO-B), which breaks down dopamine in the brain.
COMT inhibitors
These medications stop an enzyme that breaks down dopamine in the brain, catechol-O-methyltransferase (COMT).
Anticholinergics
These medications can be helpful for reducing tremor and muscle contractions in cases of “wearing off” or when a patient has symptoms before the are ablet to take more medication. They work by reducing the action of a neurotransmitter called acetylcholine that is involved in activating muscles.
Antipsychotics
These drugs are used to treat the hallucinations and delusions that some people with Parkinson’s disease experience.
Antidepressants
People with Parkinson’s disease are at higher risk for developing depression. Antidepressants can help relieve these symptoms.
Stimulants
People with Parkinson’s disease can develop excessive daytime sleepiness. Stimulants can help combat this symptom.
Cholinesterase inhibitors
These drugs are used to treat dementia, or memory and thinking problems, due to aging and the progression of Parkinson’s disease.

The Takeaway

  • Parkinson’s disease is a chronic illness, but medications can help lessen symptoms.
  • There are three key types of medications used to treat Parkinson’s disease.
  • These medications may increase the level of dopamine in your brain, affect other neurotransmitters, or help control motor and nonmotor symptoms
jason-paul-chua-bio

Jason Paul Chua, MD, PhD

Medical Reviewer

Jason Chua, MD, PhD, is an assistant professor in the Department of Neurology and Division of Movement Disorders at Johns Hopkins School of Medicine. He received his training at the University of Michigan, where he obtained medical and graduate degrees, then completed a residency in neurology and a combined clinical/research fellowship in movement disorders and neurodegeneration.

Dr. Chua’s primary research interests are in neurodegenerative disease, with a special focus on the cellular housekeeping pathway of autophagy and its impact on disease development in diseases such as Parkinson disease. His work has been supported by multiple research training and career development grants from the National Institute of Neurological Disorders and Stroke and the American Academy of Neurology. He is the primary or coauthor of 14 peer-reviewed scientific publications and two peer-reviewed online learning modules from the American Academy of Neurology. He is also a contributing author to The Little Black Book of Neurology by Osama Zaldat, MD and Alan Lerner, MD, and has peer reviewed for the scientific journals Autophagy, eLife, and Neurobiology of Disease.

erin-archer-kelser-bio-final

Erin Archer Kelser, RN

Author

Erin Archer Kelser, RN, is a freelance health writer and registered nurse in the Tucson, Arizona, area. She has written for the Institut Pasteur, AuntMinnie.com, and the Catholic Health Association. She has a degrees in both English and nursing.

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Parkinson's Disease. Mayo Clinic. September 27, 2024.
  2. Pringsheim T et al. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary. Neurology. November 16, 2021.
  3. Levodopa and Carbidopa. MedlinePlus. June 20, 2024.
  4. FDA approves new levodopa/carbidopa formulation for use in Parkinson’s. Michael J. Fox Foundation. August 8, 2024.
  5. U.S. FDA Approves VYALEV™ (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease. Abbvie. October 17, 2024.
  6. Dyskensia. Michael J. Fox Foundation. October 22, 2024.
  7.  'Off' Time in Parkinson’s Disease . Michael J. Fox Foundation. April 17, 2024.
  8. Choi J et al. Dopamine Agonists. StatPearls. June 26, 2023.
  9. Droxidopa Oral Route. Mayo Clinic. January 31, 2024.
  10. Compulsive Gambling. Mayo Clinic. June 18, 2022.
  11. Dopamine Agonists. Cleveland Clinic. May 9, 2023.
  12. MAO-B inhibitors (rasagiline, selegiline, safinamide). Parkinson's UK. August 2019.
  13. COMT Inhibitors. Parkinson's UK. August 2019.
  14. Amantadine Oral Capsules or Tablets. Cleveland Clinic. 2024.
  15. Anticholinergics (procyclidine, trihexyphenidyl). Parkinson's UK. August 2019.
  16. Anticholinergic Drugs. Parkinson's Foundation.
  17. Antipsychotic Medications. Cleveland Clinic. February 12, 2023.
  18. Hallucinations/Delusions. Parkinson's Foundation.
  19. Depression. Parkinson's Foundation.
  20.  Sleep and Parkinson's Disease. Michael J. Fox Foundation. Spring 2021.
  21. Pagano G et al. Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis. Movement Disorders. October 8, 2019.
Additional Sources
  • Brooks DJ. Dopamine Agonists: Their Role in the Treatment of Parkinson’s Disease. Journal of Neurology, Neurosurgery & Psychiatry. June 2000.
  • Giladi N, Weitzman N, Schreiber S, et al. New Onset Heightened Interest or Drive for Gambling, Shopping, Eating or Sexual Activity in Patients With Parkinson’s Disease: The Role of Dopamine Agonist Treatment and Age at Motor Symptoms Onset. Journal of Psychopharmacology. July 2007.
  • Finberg JPM, Rabey JM. Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology. Frontiers in Pharmacology. 2016.
  • COMT Inhibitors. Parkinson’s Foundation.
  • Divac N, Stojanovic R, Vujovic KS, et al. The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients With Parkinson’s Disease. Behavioral Neurology. 2016.
  • Frenklach A. Management of Depression in Parkinson’s Disease. The American Journal of Psychiatry. April 1, 2016.
  • Loddo G, Calandra-Buonaura G, Sambati L, et al. The Treatment of Sleep Disorders in Parkinson’s Disease: From Research to Clinical Practice. Frontiers in Neurology. 2017.
  • Lewis R. Menopause and Parkinson’s. Parkinson’s UK.